谷歌浏览器插件
订阅小程序
在清言上使用
VIPCreated with Sketch.
研究兴趣

论文共 17 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
431P Exposure-adjusted Incidence Rates (eairs) of Adverse Events (aes) from the TROPION-Breast01 Study of Datopotamab Deruxtecan (Dato-Dxd) Vs Investigator’s Choice of Chemotherapy (ICC) in Patients (pts) with Pretreated, Inoperable/metastatic HR+/HER2– Breast Cancer (BC)
H.S. Rugo, A. Bardia,S-A. Im,S. Pernas Simon,M. De Laurentiis, S. Wang, N. Martinez, G. Santos Borges, D. Cescon, M. Hattori,Y-S. Lu, J. Tsurutani, S.M. Tolaney, D. Mapiye, K. Atuah, D. Verma, S. Khan, B. Xu, B. Pistilli, K. Jhaveri
Annals of Oncology (2024)
引用0浏览0引用
0
0
235MO Efficacy and Safety of Ribociclib (RIB) + Nonsteroidal Aromatase Inhibitor (NSAI) in Younger Patients (pts) with HR+/HER2− Early Breast Cancer (EBC) in NATALEE
S. Loi, E. Stringer-reasor, J-S. Frenel, M. Reinisch, R. ORegan,M. De Laurentiis, Y.H. Park, A. O'Dea,Y-S. Lu, V. Gonzalez, M. Gao, S. Waters, H. Hu, B. Xu
Annals of Oncology (2024)
引用0浏览0引用
0
0
Capivasertib (C) plus fulvestrant (F) for patients (pts) with aromatase inhibitor (AI)-resistant HR+/HER2e advanced breast cancer (ABC): Phase III CAPItello-291 trial Chinese cohort
X. Hu,Q. Zhang, T. Sun,H. Xiong, W. Li,Y. Teng,Y-S. Lu,L-M. Tseng, M. Yan, H. Li, D. Pang,S. C. Chen, W. Chen,O. Jiang, J. Wang, X. Wu, E. Fan, L. Jiang, X. Zeng, N. Turner
ANNALS OF ONCOLOGY (2023): S1485-S1486
引用0浏览0引用
0
0
加载更多
作者统计

#Papers: 17

#Citation: 644

H-Index: 8

G-Index: 17

Sociability: 5

Diversity: 0

Activity: 0

  • 合作者
  • 学生
  • 导师
暂无相似学者，你可以通过学者研究领域进行搜索筛选
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn